IL10 and arthritic joint disease: Furthermore, Mancheño-Corvo et al. demonstrated that eASCs administered IN reduced systemic inflammation, in an experimental model of arthritis, by inducting CD25+Foxp3+CD4+ cells and IL10+CD4+ cells in the LNs and in the spleen (27).